The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chvatchko, Y.
Right arrow Articles by Wells, T. N. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chvatchko, Y.
Right arrow Articles by Wells, T. N. C.
The Journal of Immunology, 2003, 171: 5498-5506.
Copyright © 2003 by The American Association of Immunologists

Inhibition of Airway Inflammation by Amino-Terminally Modified RANTES/CC Chemokine Ligand 5 Analogues Is Not Mediated through CCR3

Yolande Chvatchko*, Amanda E. I. Proudfoot1,*, Raphaële Buser*, Pierre Juillard*, Sami Alouani*, Marie Kosco-Vilbois2,*, Anthony J. Coyle3,*, Robert J. Nibbs{dagger}, Gerry Graham{dagger}, Robin E. Offord{ddagger} and Timothy N. C. Wells*

* Serono Pharmaceutical Research Institute, Plan les Ouates, Geneva, Switzerland; {dagger} Beatson Institute for Cancer Research, Cancer Research United Kingdom Beatson Laboratories, Bearsden, Glasgow, United Kingdom; and {ddagger} Département de Biochimie Médicale, Centre Medicale Universitaire, Geneva, Switzerland

Chemokines play a key role in the recruitment of activated CD4+ T cells and eosinophils into the lungs in animal models of airway inflammation. Inhibition of inflammation by N-terminally modified chemokines is well-documented in several models but is often reported with limited dose regimens. We have evaluated the effects of doses ranging from 10 ng to 100 µg of two CC chemokine receptor antagonists, Met-RANTES/CC chemokine ligand 5 (CCL5) and aminooxypentane-RANTES/CCL5, in preventing inflammation in the OVA-sensitized murine model of human asthma. In the human system, aminooxypentane-RANTES/CCL5 is a full agonist of CCR5, but in the murine system neither variant is able to induce cellular recruitment. Both antagonists showed an inverse bell-shaped inhibition of cellular infiltration into the airways and mucus production in the lungs following allergen provocation. The loss of inhibition at higher doses did not appear to be due to partial agonist activity because neither variant showed activity in recruiting cells into the peritoneal cavity at these doses. Surprisingly, neither was able to bind to the major CCR expressed on eosinophils, CCR3. However, significant inhibition of eosinophil recruitment was observed. Both analogues retained high affinity binding for murine CCR1 and murine CCR5. Their ability to antagonize CCR1 and CCR5 but not CCR3 was confirmed by their ability to prevent RANTES/CCL5 and macrophage inflammatory protein-1{beta}/CCL4 recruitment in vitro and in vivo, while they had no effect on that induced by eotaxin/CCL11. These results suggest that CCR1 and/or CCR5 may be potential targets for asthma therapy.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
Y. Suzaki, K. Hamada, T. Nomi, T. Ito, M. Sho, Y. Kai, Y. Nakajima, and H. Kimura
A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation
Eur. Respir. J., April 1, 2008; 31(4): 783 - 789.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Gupta, B. Fuchs, S. Schulz-Maronde, A. Heitland, S. E. Escher, M. Mack, H.-C. Tillmann, A. Braun, W.-G. Forssmann, J. Elsner, et al.
Intravascular inactivation of CCR5 by n-Nonanoyl-CC chemokine ligand 14 and inhibition of allergic airway inflammation
J. Leukoc. Biol., March 1, 2008; 83(3): 765 - 773.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Mellado, A. M. de Ana, L. Gomez, C. Martinez-A, and J. M. Rodriguez-Frade
Chemokine Receptor 2 Blockade Prevents Asthma in a Cynomolgus Monkey Model
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 769 - 775.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. L. Ness, J. L. Ewing, C. M. Hogaboam, and S. L. Kunkel
CCR4 Is a Key Modulator of Innate Immune Responses
J. Immunol., December 1, 2006; 177(11): 7531 - 7539.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
S. Schnyder-Candrian, D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. Fossiez, B. Ryffel, and B. Schnyder
Interleukin-17 is a negative regulator of established allergic asthma
J. Exp. Med., November 27, 2006; 203(12): 2715 - 2725.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Ma, W. Liu, R. J. Homer, P. J. Lee, A. J. Coyle, J. M. Lora, C. G. Lee, and J. A. Elias
Role of CCR5 in the Pathogenesis of IL-13-Induced Inflammation and Remodeling.
J. Immunol., April 15, 2006; 176(8): 4968 - 4978.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. M. Kish-Catalone, W. Lu, R. C. Gallo, and A. L. DeVico
Preclinical Evaluation of Synthetic -2 RANTES as a Candidate Vaginal Microbicide To Target CCR5.
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1497 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
N. R. Veillard, B. Kwak, G. Pelli, F. Mulhaupt, R. W. James, A. E.I. Proudfoot, and F. Mach
Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice
Circ. Res., February 6, 2004; 94(2): 253 - 261.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.